Felzartamab

Monoclonal antibody

Also known as MOR202, TJ202

Partialsignal

Evidence outlook · lead readout

NCT03952091 · Multiple Myeloma in Relapse, Refractory Multiple Myeloma

The completed lead evidence is positive, with design limits that temper confidence; the rationale below says which.

NCT03952091: This was a large (n=289), randomized, active-controlled Phase 3 trial using a well-accepted hard clinical endpoint (progression-free survival), and the drug combination showed a statistically significant improvement over the active comparator. However, the trial was conducted completely open-label with no blinding of patients or investigators, which limits confidence in the result despite its objective endpoint and statistical significance.

Also in development:IgA Nephropathy · Phase 3Primary Membranous Nephropathy · Phase 3

Development in Systemic Lupus Erythematosus stopped (2022-12-14) as a strategic decision by the sponsor. Source

Company guidance: data expected H1 2027 (NCT06685757; Biogen, 19 Oct 2026). “Data from the TRANSCEND study is expected in H1 2027.” Source ↗

The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (5)
IgA Nephropathy
NCT06935357 · Biogen
2025-05-08 – 2029-06-05 · Immunoglobulin A Nephropathy (IgAN)
What this study did
Multiple Myeloma
Primary Membranous Nephropathy
NCT06962800 · Biogen
2025-05-22 – 2031-01-17 · Primary Membranous Nephropathy
What this study did
Other / comorbidity
NCT06685757 · Biogen
2024-12-03 – 2027-06-01 · Antibody-mediated Rejection
What this study did
Phase 2 (9)
IgA Nephropathy
NCT07889362 · Biogen
2026-11-16 – 2029-12-02 · Immunoglobulin A Nephropathy
What this study did
NCT05065970 · HI-Bio, A Biogen Company
2021-08-31 – 2024-05-06 · Immunoglobulin A (IgA) Nephropathy
What this study did
Multiple Myeloma
NCT03860038 · TJ Biopharma Co., Ltd.
2019-01-28 – 2023-01-28 · Multiple Myeloma in Relapse, Refractory Multiple Myeloma
What this study did
Other / comorbidity
NCT07939802 · Biogen
2026-11-19 – 2029-03-20 · Generalized Myasthenia Gravis
What this study did
NCT07722546 · Biogen
2026-07-30 – 2028-03-31 · Graves' Disease
What this study did
NCT07219043 · Biogen
2026-01-05 – 2028-02-10 · Microvascular Inflammation
What this study did
NCT04893096 · Mario Negri Institute for Pharmacological Research
2021-10-22 – 2025-02-21 · Membranous Nephropathy
What this study did
NCT05021484 · Farsad Eskandary
2021-10-06 – 2024-03-07 · Antibody-mediated Rejection
What this study did
NCT04733040 · HI-Bio, A Biogen Company
2021-01-20 – 2023-12-14 · Glomerulonephritis, Membranous Nephropathy, antiPLA2R Positive
What this study did
Phase 1/2 (1)
Other / comorbidity
NCT04145440 · HI-Bio, A Biogen Company
2019-10-15 – 2022-08-02 · Glomerulonephritis, Membranous, antiPLA2R Positive
What this study did
Phase 1 (3)
Other / comorbidity
NCT06064929 · HI-Bio, A Biogen Company
2023-11-01 – 2026-07-08 · Lupus Nephritis
What this study did
NCT06285201 · TJ Biopharma Co., Ltd.
2024-03-27 – 2024-08-15 · Healthy
What this study did
NCT05140824 · TJ Biopharma Co., Ltd.
2021-12-30 – 2022-12-14 · Systemic Lupus Erythematosus (SLE)
What this study did

Competitive landscape

This mechanism is crowded: 13 other tracked programmes target it, 2 of them ahead of this one.

This drug's own stage for IgA Nephropathy: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Felzartamab: this drugPhase 3Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication
AtaciceptApprovedProtein / enzyme therapeuticBLyS/APRIL (B-cell activating factor/a proliferation-inducing ligand)Partial signalFeatured results are non-efficacy only in this race
Atrasentan (Vanrafia)ApprovedSmall moleculeEndothelin A receptorPartial signal
NCT04573478: Primary (interim, first 270 patients): 24-hour UPCR change at week 36, atrasentan -38.1% vs placebo -3.1%; between-group difference -36.1 percentage points (95% CI -44.6 to -26.4), P<0.001
Budesonide (targeted-Release) (TARPEYO / Nefecon)ApprovedSmall moleculeGlucocorticoid receptorReliable signalNo reviewed efficacy summary in this indication
Iptacopan (Fabhalta)ApprovedSmall moleculeComplement Factor BPartial signal
NCT04578834: Final analysis: annualized total eGFR slope over 24 months, iptacopan -3.10 vs placebo -6.12 mL/min/1.73 m2 per year; difference 3.02 (95% CI 2.02 to 4.01), adjusted P<0.001. Interim (month 9): 24-hour UPCR 38.3% lower with iptacopan (95% CI 26.0 to 48.6), P<0.001. Both primaries met.
Ravulizumab (Ultomiris)ApprovedMonoclonal antibodyComplement C5Partial signal
NCT06291376: Primary 1, change in 24-hour UPCR at week 34 (prespecified interim analysis), ravulizumab vs placebo: the sponsor reports a statistically significant and clinically meaningful reduction, met; figures not yet published. Primary 2, change in eGFR at week 106: not yet reported; the trial is ongoing.
Sparsentan (Filspari)ApprovedSmall moleculeAngiotensin II receptor type 1 (AT1R) + Endothelin receptor type A (ETA)Partial signalFeatured results are non-efficacy only in this race
JADE101Phase 3Monoclonal antibodyAPRIL (A Proliferation-Inducing Ligand, TNFSF13)not yet gradedNo reviewed efficacy summary in this indication
MezagitamabPhase 3Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication
PovetaciceptPhase 3Protein / enzyme therapeuticBAFF / APRILnot yet gradedNo reviewed efficacy summary in this indication
SefaxersenPhase 3RNA / oligonucleotideComplement factor B (CFB)Partial signal
NCT05797610: Prespecified interim analysis: statistically significant reduction in proteinuria (24-hour UPCR) vs placebo at week 37 (2026-09-23).
TelitaciceptPhase 3Protein / enzyme therapeuticBAFF / APRILnot yet gradedNo reviewed efficacy summary in this indication
ZigakibartPhase 3Monoclonal antibodyAPRIL (A Proliferation-Inducing Ligand, TNFSF13)not yet gradedNo reviewed efficacy summary in this indication
Ebribafusp AlfaPhase 2Protein / enzyme therapeuticC3d / Factor Hnot yet gradedNo reviewed efficacy summary in this indication
SCTC21CPhase 1/2Biologic (subtype unspecified)CD38not yet gradedNo reviewed efficacy summary in this indication
ARO-CFBPhase 1RNA / oligonucleotideComplement factor B (CFB) mRNAnot yet gradedNo reviewed efficacy summary in this indication
Opemalirsen
Phase 1(overall)
RNA / oligonucleotide—not yet gradedNo reviewed efficacy summary in this indication

Compare side by side

5 further pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.

Upcoming events

(8 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Felzartamab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 3Antibody-mediated RejectionActive not recruiting
Est. primary completion 2026-12-01 · NCT06685757 · CT.gov ↗

Company guidance: data expected H1 2027 (Biogen, 19 Oct 2026). “Data from the TRANSCEND study is expected in H1 2027.” Source ↗

What to watch
2027 (1)
May 2027 (1)
Phase 3IgA NephropathyRecruiting
Est. primary completion 2027-05-31 · NCT06935357 · CT.gov ↗
What to watch
2028 (4)
January 2028 (1)
Phase 2Graves' DiseaseRecruiting
Est. primary completion 2028-01-31 · NCT07722546 · CT.gov ↗
What to watch
February 2028 (1)
Phase 2Microvascular InflammationRecruiting
Est. primary completion 2028-02-10 · NCT07219043 · CT.gov ↗
What to watch
August 2028 (1)
Phase 2IgA NephropathyNot yet recruiting
Est. primary completion 2028-08-13 · NCT07889362 · CT.gov ↗
What to watch
September 2028 (1)
Phase 2Generalized Myasthenia GravisNot yet recruiting
Est. primary completion 2028-09-19 · NCT07939802 · CT.gov ↗
What to watch
2030 (1)
January 2030 (1)
Phase 3Primary Membranous NephropathyRecruiting
Est. primary completion 2030-01-28 · NCT06962800 · CT.gov ↗
What to watch
2031 (1)
December 2031 (1)
Phase 3Antibody-mediated Rejection, Microvascular InflammationEnrolling by invitation
Est. primary completion 2031-12-31 · NCT07444489 · CT.gov ↗
What to watch

See the full readout calendar ↗